We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
+9.54%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$109B
AUM Growth
+$10.1B
Cap. Flow
+$2.06B
Cap. Flow %
1.89%
Top 10 Hldgs %
23.41%
Holding
4,156
New
227
Increased
1,649
Reduced
1,885
Closed
242

Sector Composition

Rank Sector Weight
1 Technology 12.51%
2 Healthcare 9.35%
3 Financials 9.21%
4 Industrials 6.82%
5 Consumer Discretionary 5.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ASG
3326
Liberty All-Star Growth Fund
ASG
$349M
$245K ﹤0.01%
49,658
-11,604
-19% -$59.9K
ALRM icon
3327
Alarm.com
ALRM
$2.74B
$245K ﹤0.01%
4,942
-1,339
-21% -$73.8K
GLU
3328
Gabelli Utility & Income Trust
GLU
$116M
$244K ﹤0.01%
17,336
-1,214
-7% -$17.4K
SXT icon
3329
Sensient Technologies
SXT
$5.53B
$244K ﹤0.01%
3,344
-7
-0.2% -$502
REI icon
3330
Ring Energy
REI
$349M
$244K ﹤0.01%
99,030
-31,771
-24% -$87.2K
LBAI
3331
DELISTED
Lakeland Bancorp Inc
LBAI
$243K ﹤0.01%
13,823
-5,266
-28% -$93.9K
RJET
3332
Republic Airways Holdings
RJET
$964M
$243K ﹤0.01%
10,605
-4,711
-31% -$96.2K
ANIX icon
3333
Anixa Biosciences
ANIX
$109M
$243K ﹤0.01%
57,217
-3,629
-6% -$17.5K
VIST icon
3334
Vista Energy
VIST
$7.33B
$243K ﹤0.01%
+15,517
New +$204K
BAUG icon
3335
Innovator US Equity Buffer ETF August
BAUG
$204M
$243K ﹤0.01%
8,100
SAGE
3336
DELISTED
Sage Therapeutics
SAGE
$240K ﹤0.01%
+6,305
New +$241K
NE icon
3337
PUT
Noble Corp
NE
$7.07B
$240K ﹤0.01%
+123,000
New +$4.37M
KEN icon
3338
Kenon Holdings
KEN
$3.53B
$240K ﹤0.01%
7,260
BHF icon
3339
Brighthouse Financial
BHF
$3.42B
$239K ﹤0.01%
4,670
-47
-1% -$2.46K
FT
3340
Franklin Universal Trust
FT
$198M
$239K ﹤0.01%
35,565
+2,524
+8% +$16.9K
EQRR icon
3341
ProShares Equities for Rising Rates ETF
EQRR
$34.2M
$239K ﹤0.01%
+4,708
New +$240K
NMCO icon
3342
Nuveen Municipal Credit Opportunities Fund
NMCO
$589M
$239K ﹤0.01%
21,714
+366
+2% +$4.08K
NARI
3343
DELISTED
Inari Medical, Inc. Common Stock
NARI
$238K ﹤0.01%
3,752
-583
-13% -$42.3K
PCM
3344
PCM Fund
PCM
$70M
$238K ﹤0.01%
30,180
+591
+2% +$4.91K
MPC icon
3345
CALL
Marathon Petroleum
MPC
$100B
$237K ﹤0.01%
56,000
-8,700
-13% -$992K
BBIN icon
3346
JPMorgan BetaBuilders International Equity ETF
BBIN
$6.59B
$237K ﹤0.01%
+4,772
New +$226K
JMOM icon
3347
JPMorgan US Momentum Factor ETF
JMOM
$2.64B
$237K ﹤0.01%
6,283
+301
+5% +$11.4K
FRDM icon
3348
Freedom 100 Emerging Markets ETF
FRDM
$3.43B
$237K ﹤0.01%
8,585
-894
-9% -$24.5K
GT icon
3349
Goodyear
GT
$1.78B
$237K ﹤0.01%
23,312
-23,645
-50% -$258K
ESPR
3350
DELISTED
Esperion Therapeutics
ESPR
$236K ﹤0.01%
+37,928
New +$271K

Similar funds

Raymond James & Associates's Q4 2022 Portfolio in Review

As of Q4 2022, Raymond James & Associates held 4,156 positions worth $109B, up 10% from $98.8B the previous quarter. Its ten largest holdings account for 23% of the portfolio.

Raymond James & Associates's Q4 2022 filing shows 227 new, 1,649 increased, 1,885 reduced and 242 closed positions. Its largest new stake was Rentokil: 285,133 shares worth $8.78M. The largest sale was iShares Expanded Tech Sector ETF, an estimated $79.2M.

By sector, the portfolio is most concentrated in Technology at 13% of assets, down from 13% a quarter earlier, followed by Healthcare and Financials.

  • Raymond James & Associates's largest Q4 2022 buy was Rentokil: 285,133 shares worth $8.78M.
  • Raymond James & Associates added most to Vanguard S&P 500 ETF in Q4 2022, an estimated $169M increase.
  • Raymond James & Associates's biggest Q4 2022 reduction was iShares Expanded Tech Sector ETF, cutting an estimated $79.2M.
  • Raymond James & Associates fully exited Change Healthcare Inc. Common Stock in Q4 2022, selling an estimated $53.3M.
  • Raymond James & Associates's ten largest holdings make up 23% of its $109B portfolio in Q4 2022.
  • Raymond James & Associates opened 227 new positions and closed 242 in Q4 2022.
  • Raymond James & Associates's portfolio value rose 10% quarter-over-quarter to $109B.

Based on Raymond James & Associates's 13F filing for Q4 2022, filed 8 Feb 2023.